Nitrite is a nitric oxide (NO) metabolite, which may be bioactivated to generate NO in vivo and supplement endogenous NO formation, especially in cardiovascular and metabolic diseases. However, it is not known whether treatment with oral nitrite results in the accumulation of NO metabolites in different organs. Moreover, treatment with omeprazole, an inhibitor of gastric acid secretion, severely affects the gastric formation of S-nitrosothiols induced with oral nitrite treatment. However, no previous study has examined whether omeprazole affects the nitrite-induced accumulation of NO metabolites in different organs. This study examined in rats the effects of oral sodium nitrite treatment (15 mg/kg via gavage for 1 or 7 days) associated with omeprazole (10 mg/kg or vehicle) on nitrite and nitrate and nitrosylated species (RXNO) concentrations (measured using ozone-based chemiluminescence methods) assessed in the plasma, aorta, heart, liver, brain, and muscle. While our results showed that NO metabolite accumulation in different organs is not uniform, we found that the skeletal muscle, the heart, and the liver accumulate NO metabolites, particularly RXNO. This response was significantly attenuated by omeprazole in the heart and in the skeletal muscle. Together, these findings may indicate that the skeletal muscle, the heart, and the liver are major reservoir sites for NO metabolites after oral nitrite treatment, with major increases in nitrosylated species.
Inorganic nitrite contributes to the nitrosation of biomolecules and exerts antioxidant effects. The proton pump inhibitor omeprazole has pro-oxidant effects, inhibits the formation of nitroso species in the stomach, and abrogates the blood pressure-lowering effects of orally administered nitrite. Here, we examine whether a two-week treatment with nitrite leads to tissue nitrosation that scales with local thiol concentrations and whether oral nitrite treatment can prevent the pro-oxidant effects of omeprazole. Male Sprague–Dawley rats received daily doses of omeprazole 10 mg/kg i.p. (or vehicle) and sodium nitrite 15 mg/kg by gavage (or water) for 14 days. Animals were euthanized 6 h after the last nitrite dose, and blood and tissues (brain, heart, and liver) were collected for biochemical analyses. We found that nitrite treatment increased liver nitrite and total nitroso species (RxNO) concentrations approximately eight-fold (with minor increases in other organs), and omeprazole treatment attenuated these effects. Nitrite treatment selectively elevated non-protein thiol concentrations in the liver, but not in animals also receiving omeprazole. Tissue thiol elevation was associated with increased nitrosation of hepatic proteins, which was prevented by omeprazole. Nitrite upregulated mRNA expression of microsomal glutathione S-transferase-1 (Mgst1) and decreased superoxide and hydrogen peroxide production, especially in rats co-treated with omeprazole. While omeprazole increased liver xanthine oxidoreductase (XOR), nitrite treatment attenuated this effect. These results demonstrate that oral nitrite treatment robustly elevates nitrite and RxNO concentrations in the liver, and these effects are associated with increased hepatic glutathione production and an upregulation of Mgst1 expression, counteracting the pro-oxidant effects induced by omeprazole.
Nitrate is bioactivated to nitrite and nitric oxide (NO) and has been used to treat cardiovascular and metabolic diseases. Patients with obesity or overweight are exposed to increased cardiovascular risk, which is in part attributable to increased matrix metalloproteinase (MMP) activity and cardiovascular remodeling. Here, we examined the effects of NO supplementation with oral nitrate treatment on the circulating concentrations of MMP-2, MMP-9, and their endogenous inhibitors, the tissue inhibitors of MMPs (TIMP-1,-2,-3 and -4) in overweight women who had previously undergone Roux-en-Y gastric bypass (RYGB) surgery (n=15), and those with no history of bariatric procedures (control, n=13). Patients received 5g of beetroot extract enriched with sodium nitrate to daily intake of 0.1 mmol/kg body weight of nitrate for 14 days. Ambulatory blood pressure monitoring, carotid-femoral pulse wave velocity (PWV), and the Augmentation Index (AIx) were assessed at baseline and after nitrate treatment. Venous blood samples were collected for biochemical analysis at baseline and after nitrate treatment. MMP-2, MMP-9, and TIMP-1,-2,-3 and -4 were assessed using two Human Luminex® Discovery Assays. Nitrite and nitrate concentrations were assessed using ozone-based reductive chemiluminescence methods. Nitrate treatment decreased net MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios (which reflect net MMP activity) in overweight control women, but not in those with previous bariatric surgery (All P<0.05). Nitrite and nitrate concentrations were negatively associated with net MMP-2 and MMP-9 activity. While VOP showed no significant differences, MMP-2 concentrations or MMP-2/TIMP-2 ratio associated positively with AIx. Our results provide evidence that nitrate treatment reduces net MMP-2 and MMP-9 activity in overweight women, highlighting its therapeutic potential to prevent cardiovascular remodeling. However, this effect appears to be attenuated in women with prior RYGB surgery.